PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation
- 1 July 2020
- journal article
- research article
- Published by Wiley in Diagnostic Cytopathology
- Vol. 48 (7), 595-603
- https://doi.org/10.1002/dc.24439
Abstract
Introduction In the selection of non-small cell lung cancer (NSCLC) patients for immunotherapy, specimen processed as cell blocks (CBs) may be the only available material to assess PD-L1 expression. Therefore, optimal CB preparation becomes paramount. In this context, here we assessed whether inadequate fixation time might be one of the pre-analytical factors affecting PD-L1 expression. Methods Ex vivo CBs from placental (n = 3) and NSCLC (n = 8) resection specimens were obtained. PD-L1 staining was performed on CBs prepared at increasing fixation times (12 hours, 48 hours, 72 hours, 96 hours, 168 hours and 504 hours) using the companion diagnostic SP263 Assay and a validated 22C3 laboratory developed test (LDT). Staining intensity and percentage of positive cells were evaluated. Results All placental CBs showed moderate to strong PD-L1 positivity in most cells, regardless of the fixation time. Likewise, the percentage of SP263-stained NSCLC cells was similar at all fixation times except for one case, which showed less intense SP263 staining at 168 hours. Conversely, in 5/8 cases, the 22C3 LDT percentage of positive cells and staining intensity decreased at 168 hours and 504 hours. Conclusions Our results show that fixation time influences the performance of 22C3 LDT on CBs. Thus, we recommend that the fixation time of cytological materials be carefully checked, especially when PD-L1 testing is delayed until the oncology request. Indeed, delays in tissue processing and paraffin embedding may lead to sub-optimal performance of PD-L1 staining on CBs.This publication has 34 references indexed in Scilit:
- Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1Archives of Pathology & Laboratory Medicine, 2016
- Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung CancerApplied Immunohistochemistry & Molecular Morphology, 2016
- FNA smears as a potential source of DNA for targeted next‐generation sequencing of lung adenocarcinomasCancer Cytopathology, 2016
- Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Cancer Biology & Medicine, 2016
- Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencingCancer Cytopathology, 2014
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancerAnnals of Oncology, 2014
- The state of cell block variation and satisfaction in the era of molecular diagnostics and personalized medicineCytojournal, 2014
- An Alternative Approach in Endocrine Pathology Research: MALDI-IMS in Papillary Thyroid CarcinomaEndocrine Pathology, 2013
- The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working groupLung Cancer, 2011
- KRAS testing on colo‐rectal carcinoma cytological imprintsDiagnostic Cytopathology, 2011